Andreas Meisel
YOU?
Author Swipe
View article: Anti-NMDA-Receptor GluN1 Antibody Serostatus Is Robust in Acute Severe Stroke
Anti-NMDA-Receptor GluN1 Antibody Serostatus Is Robust in Acute Severe Stroke Open
Background: Anti-N-methyl-D-aspartate IgM and IgA antibodies (NMDAR1-abs) are associated with unfavorable stroke outcomes and may be risk factors thereof. However, to utilize NMDAR1-abs serostatus for risk assessment in acute stroke, it is…
View article: Paraneoplastic Lambert–Eaton myasthenic syndrome associated with non-small cell lung cancer: data from the European LEMS registry and systematic review
Paraneoplastic Lambert–Eaton myasthenic syndrome associated with non-small cell lung cancer: data from the European LEMS registry and systematic review Open
Background Paraneoplastic Lambert-Eaton myasthenic syndrome (pLEMS) is well-established in small-cell lung cancer (SCLC), but data on other malignancies are limited. We aimed to define the clinical phenotype of pLEMS in non-SCLC cancers (n…
View article: Prediction of Myasthenia Gravis Worsening: A Machine Learning Algorithm Using Wearables and Patient‐Reported Measures
Prediction of Myasthenia Gravis Worsening: A Machine Learning Algorithm Using Wearables and Patient‐Reported Measures Open
Background Myasthenia gravis (MG) is a rare disorder characterized by fluctuating muscle weakness with potential life‐threatening crises. Timely interventions may be delayed by limited access to care and fragmented documentation. Our objec…
View article: Robotic Extended Thymectomy in Late‐Onset Myasthenia Gravis: A 21‐Year Retrospective Cohort Study of 172 Patients
Robotic Extended Thymectomy in Late‐Onset Myasthenia Gravis: A 21‐Year Retrospective Cohort Study of 172 Patients Open
Background The safety and feasibility of robotic‐assisted (RATS) thymectomy for myasthenia gravis (MG) with onset age ≥ 50 years remain unverified, particularly in very late‐onset MG (V‐LOMG). Methods Patients were classified into late‐ons…
View article: AXIN1, STAMBP, ST1A1, CDCP1, and SIRT2 Validated as Myasthenia Gravis Biomarkers: A Comparative Proteomic Study With MS, CIDP, and Controls
AXIN1, STAMBP, ST1A1, CDCP1, and SIRT2 Validated as Myasthenia Gravis Biomarkers: A Comparative Proteomic Study With MS, CIDP, and Controls Open
Background and Purpose Myasthenia gravis (MG) lacks disease‐specific biomarkers that can support monitoring of disease activity or guide treatment decisions. This study aimed to validate serum inflammatory proteins as MG‐specific biomarker…
View article: Protocol to validate custom-designed BaseScope probes using cell-free synthesized protein lysates and in vitro-transcribed purified mRNA
Protocol to validate custom-designed BaseScope probes using cell-free synthesized protein lysates and in vitro-transcribed purified mRNA Open
BaseScope is an ultra-sensitive in situ hybridization technique specifically designed for detection of rare, short RNA molecules, particularly enabling co-detection of exon junctions in splice variants. Its use is cost intensive due to req…
View article: Robotic-assisted thymectomy for locally advanced thymic malignancy: technical refinement and oncologic outcomes from a 20-year cohort
Robotic-assisted thymectomy for locally advanced thymic malignancy: technical refinement and oncologic outcomes from a 20-year cohort Open
r-ThX is a viable alternative to sternotomy for selected patients with locally advanced thymic malignancies with partial invasions. Conversion to open surgery is crucial for major vessel involvement.
View article: Calprotectin and neurofilament serum levels correlate with treatment response in myasthenia gravis under intensified therapy–A pilot study
Calprotectin and neurofilament serum levels correlate with treatment response in myasthenia gravis under intensified therapy–A pilot study Open
Our preliminary findings suggest that markers of systemic inflammation (such as sCLP) and local destruction of the neuromuscular junction (such as sNfL) may assist in treatment decision-making for gMG patients. Larger, multicenter studies …
View article: Anxiety in Myasthenia Gravis Patients Throughout the COVID‐19 Pandemic–Prevalence, Risk Factors, and Association With Vaccination Status
Anxiety in Myasthenia Gravis Patients Throughout the COVID‐19 Pandemic–Prevalence, Risk Factors, and Association With Vaccination Status Open
Introduction A high prevalence of COVID‐19‐related anxiety was observed among the general population during the COVID‐19 pandemic. Patients with myasthenia gravis (MG) might be at higher risk for COVID‐19‐related anxiety due to immunosuppr…
View article: Artificial intelligence for prediction of atrial fibrillation in the stroke unit: a retrospective derivation validation cohort study
Artificial intelligence for prediction of atrial fibrillation in the stroke unit: a retrospective derivation validation cohort study Open
This study was supported by the German Federal Ministry of Education and Research and the German Research Foundation.
View article: Recruiting patients into a healthcare services trial: lessons learned from a feasibility study to investigate a patient-oriented navigation intervention for age-associated diseases
Recruiting patients into a healthcare services trial: lessons learned from a feasibility study to investigate a patient-oriented navigation intervention for age-associated diseases Open
Background Interventions to improve care coordination, like patient navigation programs, aim to dismantle barriers faced by patients in accessing optimal care. A variety of interventions are currently being evaluated in Germany and interna…
View article: Recanalization and reperfusion in clinically-relevant porcine model of stroke
Recanalization and reperfusion in clinically-relevant porcine model of stroke Open
Introduction Stroke is a leading cause of death and long-term disability. Pigs have been considered an ideal large animal model in biomedicine; however, the complex vascular anatomy has posed challenges for stroke research. Nonetheless, we…
View article: D.5 Efgartigimod treatment in participants with anti-acetylcholine receptor seronegative generalized myasthenia Myasthenia Gravis clinical studies
D.5 Efgartigimod treatment in participants with anti-acetylcholine receptor seronegative generalized myasthenia Myasthenia Gravis clinical studies Open
Background: Antibodies directed against acetylcholine receptor (AChR) are absent in approximately 15% of patients with gMG. Approved treatment options represent an unmet need in the AChR-antibody (Ab)- gMG population. Efgartigimod is an im…
View article: Assessing post-stroke cognition in pre-clinical models: lessons and recommendations from a multi-center study
Assessing post-stroke cognition in pre-clinical models: lessons and recommendations from a multi-center study Open
Cognitive decline is a significant long-term consequence of stroke and has no available treatments. To aid in therapy development, we sought to achieve robust detection of cognitive performance after stroke in a multi-site design. Ischemic…
View article: <scp>ADAPT NXT</scp>: Fixed Cycles or Every‐Other‐Week <scp>IV</scp> Efgartigimod in Generalized Myasthenia Gravis
<span>ADAPT NXT</span>: Fixed Cycles or Every‐Other‐Week <span>IV</span> Efgartigimod in Generalized Myasthenia Gravis Open
Objective This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks bet…
View article: The burden of disease in seronegative myasthenia gravis: a patient-centered perspective
The burden of disease in seronegative myasthenia gravis: a patient-centered perspective Open
Objective Myasthenia gravis (MG) is an autoimmune disorder primarily caused by autoantibodies against the acetylcholine receptor (AChR). Approximately 15% of MG patients, categorized as seronegative (snMG), lack detectable antibodies. Due …
View article: Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension
Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension Open
Background Ravulizumab, an anti‐complement C5 monoclonal antibody, was efficacious with acceptable safety in the randomized controlled period (RCP) and interim open‐label extension (OLE) periods of the CHAMPION MG phase 3 trial in adults w…
View article: Single-Cell Transcriptomics Identifies a Prominent Role for the MIF-CD74 Axis in Myasthenia Gravis Thymus
Single-Cell Transcriptomics Identifies a Prominent Role for the MIF-CD74 Axis in Myasthenia Gravis Thymus Open
Our data not only illustrate and define hyperplastic thymic niches in MG as favorable environments for pathogenic B-cell proliferation, maturation, and persistence but also suggest that the MIF-CD74 axis should be investigated for potentia…
View article: Early Complications After Mild to Moderate Ischemic Stroke and Impact on 3‐Month Outcome: The Multicenter Prospective Stroke Unit Plus Cohort Study
Early Complications After Mild to Moderate Ischemic Stroke and Impact on 3‐Month Outcome: The Multicenter Prospective Stroke Unit Plus Cohort Study Open
Background Early stroke complications (ESCs) impair recovery and provide an important therapeutic target. Our multicenter prospective cohort study examined the prevalence and amount of poor outcomes attributable to ESCs. Methods and Result…
View article: <i>Ide</i> Copy Number Variant Does Not Influence Stroke Severity in 2 C57BL/6J Mouse Models nor in Humans: An Exploratory Study
<i>Ide</i> Copy Number Variant Does Not Influence Stroke Severity in 2 C57BL/6J Mouse Models nor in Humans: An Exploratory Study Open
BACKGROUND: Contrary to the common belief, the most commonly used laboratory C57BL/6J mouse inbred strain presents a distinctive genetic and phenotypic variability, and for several traits, the genotype-phenotype link remains still unknown.…
View article: C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis
C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis Open
Background Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions, leading to fluctuating muscle weakness. While many patients respond well to standard immunosuppression, a substantial subgroup faces ongoing dis…
View article: Multicentre prospective, randomised open-label, endpoint-blinded study to evaluate the safety and efficacy of propranolol for the prevention of stroke-associated pneumonia in patients with intracerebral haemorrhage (PROCHASE): rationale and design
Multicentre prospective, randomised open-label, endpoint-blinded study to evaluate the safety and efficacy of propranolol for the prevention of stroke-associated pneumonia in patients with intracerebral haemorrhage (PROCHASE): rationale and design Open
Background Stroke-induced transient immune suppression is believed to contribute to post-stroke infections. The β-adrenergic receptor antagonist, propranolol, has been shown to prevent stroke-associated pneumonia (SAP) via reversing post-s…
View article: App- and Wearable-Based Remote Monitoring for Patients With Myasthenia Gravis and Its Specialists: Feasibility and Usability Study
App- and Wearable-Based Remote Monitoring for Patients With Myasthenia Gravis and Its Specialists: Feasibility and Usability Study Open
Background Myasthenia gravis (MG) is rare, chronic autoimmune disorder of the neuromuscular junction that requires specialized care and often lifelong treatment, facing challenges due to its rarity and the limited availability of specialis…
View article: The telemedical platform MyaLink for remote monitoring in myasthenia gravis – rationale and protocol for a proof of concept study
The telemedical platform MyaLink for remote monitoring in myasthenia gravis – rationale and protocol for a proof of concept study Open
Rationale: Myasthenia gravis (MG) is a rare, chronic neurological disorder leading to fluctuating muscle weakness and potentially life-threatening crises. Patients often require life-long specialized treatment, but timely interventions are…
View article: Ravulizumab and Efgartigimod in Myasthenia Gravis
Ravulizumab and Efgartigimod in Myasthenia Gravis Open
This study provides Class III evidence that in AChR-Ab-positive patients with generalized MG, ravulizumab and efgartigimod provide comparable modest improvement in MG functional scales.